First-in-Class Regenerative Therapeutic for AD Promising

Allopregnanolone has the potential to delay neurodegeneration in early Alzheimer's disease by promoting endogenous systems of renewal and repair, early testing shows.

Related Keywords

Rebecca Edelmayer ,Roberta Brinton ,National Institute On ,Alzheimer Association ,University Of Arizona ,Clinical Trials ,Brain Science ,Mini Mental State Examination ,National Institute ,Medscape Medical News ,Medscape Medical ,Alzheimers Disease ,Lzheimer Disease ,Antidementia Agents ,Experimental Drug ,Dementia ,Brain ,Elderly Concerns Of Older Adults ,Amyloid Beta ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Amyloid Plaque ,Clinical Research ,Linical Studies ,Drug Development ,Geriatrics Elder Care ,Medical Innovations ,Nnovations In ,